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Absorptive hypercalciuria (AH), a common stone-forming
condition characterized biochemically by intestinal
hyperabsorption of calcium and hypercalciuria may be
associated with bone loss. In AH type I (AH-1), hypercalciuria
persists despite restriction in dietary calcium intake. We
therefore hypothesized that the skeleton may contribute to
the hypercalciuria in this subgroup of patients.
Histomorphometric analysis of iliac crest biopsies were
performed on nine stone-formers with AH-1 and on nine
matched normal subjects. After stabilization on a
stone-prevention diet, calcium homeostasis in the stone
formers was then evaluated on inpatient constant metabolic
diet before and after short-term blockade of bone resorption
by alendronate (10 mg daily, 17 days total). Compared with
controls, the stone-formers had lower indices of bone
formation (osteoblast surface/bone surface 1.872.1 vs
3.071.5%, P¼ 0.04; wall thickness 35.876.9 vs 47.277.6%,
P¼ 0.001) and relatively higher bone resorption (osteoclast
surface/bone surface 0.470.2 vs 0.270.2%, P¼ 0.05). In
the stone-formers, a short-term course of alendronate
treatment corrected fasting urinary calcium (0.1470.06 to
0.0670.04 mg Ca/mg Cr, P¼ 0.001) and marginally reduced
24-h urinary calcium by 48 mg/day (P¼ 0.06). Increased
intestinal calcium absorption and hypercalciuria persisted,
but estimated calcium balance improved (P¼ 0.007). Our
results suggest that the hypercalciuria of AH-1 originates
primarily from intestinal hyperabsorption of calcium, but
bone resorption in excess of bone formation may contribute.
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Absorptive hypercalciuria (AH), a common cause of calcar-
eous renal stones, is characterized by hypercalciuria primarily
driven by intestinal hyperabsorption of calcium.1 We have
previously separated AH into type I (AH-I), in which
hypercalciuria decreases but persists after restriction of
dietary calcium, and type II (AH-II), in which hypercalciuria
resolves with restriction of dietary calcium. Although fasting
hypercalciuria, a crude marker of bone resorption, was
reported to be absent in the original description of AH-1,1 we
have since observed it in patients with higher urinary calcium
and intestinal calcium absorption.2,3 However, we attributed
the fasting hypercalciuria to delayed calcium absorption
because it corrected after treatment with sodium cellulose
phosphate, a poorly absorbed calcium binder.4
Several lines of evidence suggest that the bone may also
contribute to the hypercalciuric phenotype of AH. Bone
mineral density (BMD) of the spine tends to be reduced in
AH-I especially if fasting hypercalciuria is also present.5 BMD
at the lumbar spine has been noted to correlate inversely with
both urinary calcium6 and intestinal calcium absorption in
stone formers.7 Moreover, two studies have found that stone-
formers are at higher risk of skeletal fracture.8,9 Finally,
hypercalciuria is associated with osteoporosis.10
The exact cause of the low BMD in AH-I is unknown.
Most of the past work had been done in stone-formers with
‘idiopathic hypercalciuria,’ in which the key tests (such as
intestinal calcium absorption) had not been measured and
the various components of hypercalciuria had not been
differentiated. Fuss et al.11 implicated an iatrogenic cause of
bone loss; unlike stone-formers who were on unrestricted
diet, radial BMD was lower in stone-formers who had been
subjected to dietary calcium restriction. Other reports
suggested that the bone loss may have been intrinsic to the
underlying cause of hypercalciuria in stone-formers. For
example, several investigators suggested that various factors,
including IL-1, IL-6, tumor necrosis factor-a, granulocyte
macrophage colony stimulation factor, prostaglandins, and
fatty acids, may have instigated both hypercalciuria and bone
loss.12–16 Pediatric hypercalciuric stone-formers had low
BMD at the time of diagnosis, before dietary restrictions
had been imposed.17,18 Gitomer et al.2 found that base
substitutions in the putative AH gene were associated with
low BMD.
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Cumulative evidence suggests that 1,25-dihydroxyvitamin
D3 (1,25(OH)2D3) may play a role in the phenotype of AH
and idiopathic hypercalciuria. At high dose, this primary
hormonal regulator of intestinal calcium absorption may
increase bone resorption and decrease collagen synthesis.19
Administration of calcitriol in normal volunteers recapitu-
lates the AH phenotype.20 1,25(OH)2D3 is elevated in
30–80% of patients with AH and its regulation is dis-
ordered.21–23 Vitamin D-receptor concentrations are in-
creased in idiopathic hypercalciuric patients and in an
animal model of hypercalciuric nephrolithiasis, genetic
hypercalciuric stone-forming rats;24,25 thus, hypercalciurics
may be more sensitive to normal serum 1,25(OH)2D3. In
fact, cultured calvariae from neonatal genetic hypercalciuric
stone-forming rats demonstrate increased bone resorption
after calcitriol exposure unlike normal rat calvariae.26 Finally,
treatment with ketoconazole, which decreases serum
1,25(OH)2D3, reduces both urinary calcium and intestinal
calcium absorption in most patients with AH.23
We hypothesized that in the subset of patients with AH-I,
bone formation may be inappropriately low relative to bone
resorption, contributing to bone loss. Accordingly, we compared
bone histomorphometric presentation of AH with matched
normal subjects and examined the physiological effect of a
short-term blockade of bone resorption by alendronate in AH-I.
RESULTS
Bone histomorphometry
Overall, stone-formers displayed a lower bone formation and
higher bone resorption compared with matched normal
volunteers (Table 1, Figure 1a and b). Two parameters of bone
formation (osteoblast surface or Ob.S/BS, P¼ 0.04; wall
thickness, P¼ 0.008) were significantly decreased in stone-
formers. Median bone formation rate (BFR/BS) also tended to
be lower in stone-formers, but did not reach significance owing
to the high variance between subjects (0.34). One parameter of
bone resorption (osteoclast surface) was significantly increased
in stone-formers (0.047). Eroded surface tended to be higher in
stone-formers (0.30). Activation frequency was not significantly
different between groups. Bone volume per tissue volume (BV/
TV) tended to be lower in stone-formers than control subjects
but the difference did not reach significance (P¼ 0.25, Table 1,
Figure 1c). Trabecular thickness (Tb.Th) was significantly
decreased in stone-formers (P¼ 0.008), but there was no
difference in trabecular number (Tb.N) or trabecular separa-
tion (Tb.Sp) (Table 1, Figure 1c). There was no evidence of a
mineralization defect in any stone-former. All patients
demonstrated normal trabecular lamellar structure as seen
with polarized light.
BMD
In AH patients, clustering below the standardized mean
reference range was observed for BMD at the spine and hip,
but not at the radius. Mean and median Z-scores of the
L2–L4 vertebrae were 0.7 and 1.0 s.d., respectively, in the
AH group (Figure 2). BMD was below the standardized mean
reference range matched for age and sex in seven patients
(including four with Z-score X1 s.d. below the mean
reference range and one other subject with Z-score of 2.5
s.d.). At the femoral neck in AH patients, BMD was below the
standardized mean in seven, but only two demonstrated Z-
score X1 s.d. below the mean. At the distal radius in AH
patients, only one patient had Z-score approaching 1 s.d.
Compared with the normal volunteers group, mean and
median BMD in AH patients trended lower at the spine and
hip, but did not achieve statistical significance (Z-score for
the L-spine, P¼ 0.49; Z-score for the femoral neck, P¼ 0.22).
Unlike the BMD in AH patients, which clustered below the
reference mean at the spine and hip, BMD in the normal
volunteers was evenly distributed at the spine and hip.
Response to alendronate in stone-formers
During treatment with alendronate, markers of bone
resorption but not bone formation decreased significantly
Table 1 | Histomorphometric analysis of cancellous bone
AH
Normal
Mean7SD Median Minimum Maximum Mean7s.d. P-value
BV/TV (%) 14.674.9 15.2 8.8 23.2 17.273.9 0.25
Tb.Th (mm) 96716 93 84 134 121722 0.008
Tb.N, No/(mm) 1.570.4 1.6 0.9 2.1 1.470.2 0.44
Tb.Sp (mm) 6177232 517 378 1066 5977119 0.67
Ob.S/BS, % 1.872.1 1.7 0.1 7.1 3.071.5 0.04
W.Th (mm) 35.876.9 34.8 29.2 46.8 47.277.6 0.008
OS/BS (%) 6.075.7 5.0 0.4 19.4 5.472.0 0.65
BFR/BS (mm3/mm2/year) 0.01270.014 0.007 0.002 0.047 0.01470.007 0.34
ES/BS (%) 3.671.8 3.1 1.7 7.2 2.671.6 0.30
Oc.S/BS (%) 0.470.2 0.5 0.1 0.7 0.270.2 0.05
Ac.f, (cycles/year) 0.470.4 0.2 0.04 1.3 0.370.1 0.80
O.Th (mm) 8.072.0 8.2 5.1 10.7 11.672.9 0.01
Mlt (days) 24.2720.4 15.9 11.5 76.8 27.1715.3 0.39
Ac.f, activation frequency; AH, absorptive hypercalciuria; BFR/BS, bone formation rate; BS, bone surface referent (½ single labeled+all double labeled surfaces); BV/TV, bone
volume per tissue volume; ES/BS, eroded surface; Mlt, mineralization lag time; Ob.S/BS, osteoblast surface; Oc.S/BS, osteoclast surface; OS/BS, osteoid surface; O.Th, osteoid
thickness; Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, trabecular separation; W.Th., wall thickness.
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(Table 2). At baseline, mean fasting urinary calcium was
elevated at 0.14 mg/mg Cr (normalo0.11);27,28 individually,
five stone-formers had fasting hypercalciuria. Treatment with
alendronate decreased fasting urinary calcium in all subjects
(P¼ 0.001) and normalized fasting urinary calcium in three
of those with fasting hypercalciuria at baseline. Serum
calcium decreased significantly (P¼ 0.004), and serum
parathyroid hormone (PTH) increased significantly from
normal to high normal (34711 to 52718; P¼ 0.0004).
There was a nonsignificant rise in serum 25-OHD and
1,25(OH)2D3 (P¼ 0.23 and 0.13, respectively).
Fractional calcium absorption increased significantly
following alendronate treatment (P¼ 0.03). Post-load urin-
ary calcium decreased (P¼ 0.03), paralleling the decline in
fasting urinary calcium. The difference between post-load
and fasting urinary calcium, an indirect measure of calcium
absorption, did not decrease.
Urinary calcium was high at baseline (4200 mg/day)
(Table 2).1,27 Following alendronate treatment, urinary
calcium declined marginally (P¼ 0.06; difference 48 mg/
day, 1.2 mmol/day; 95% CI 143 to 14 mg/day, 3.6 to
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Figure 1 | Comparison of bone histomorphometry indices from iliac crest samples between patients with AH and matched normal
subjects. (a) Parameters of bone formation, (b) parameters of bone resorption, (c) structural parameters. *Po0.05, **Po0.01.
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Figure 2 | BMD at the lumbar spine, femoral neck, and distal
radius in patients with AH compared with matched controls and
to the standard reference range matched for age and gender.
The mean reference range is symbolized by the long horizontal
dashed line.
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0.4 mmol/day) and normalized in three subjects. Yet, mean
urinary calcium remained slightly elevated. The mean
decrement in urinary calcium tended to be greater in patients
with fasting hypercalciuria (71779 mg vs 22735 mg), but
this difference did not reach statistical significance (P¼ 0.29).
DISCUSSION
In patients with AH-1, we found that excess bone loss may
contribute to the hypercalciuria. We documented histomor-
phometrical evidence of low bone formation and relatively
increased bone resorption in patients with AH compared
with a matched control group. A physiologic blockade of
bone resorption with alendronate restored the originally
described biochemical presentation of AH-11,27,28 by normal-
izing fasting urinary calcium.
Prior studies examined bone histomorphometric picture
among patients with kidney stones.29–35 However, most
reports involved patients with idiopathic hypercalciuria
without a clear identification of AH, used differing defini-
tions of hypercalciuria, employed control groups that were
not matched for age and weight, and did not label the bone
with tetracycline or provide complete data. In two articles,
only subjects with low BMD were evaluated.33,35 Not
surprisingly, the published results of bone histomorphometry
have yielded conflicting results. Although most studies found
a tendency toward low bone formation without a miner-
alization defect, two articles reported high bone formation
and resorption.29,34 One study found a mineral defect with
increased osteoid thickness and increased mineralization lag
time, but serum 25-OHD was not provided.34 Another study
reported hyperosteoidosis, but osteoid thickness and miner-
alization lag-time were omitted, leaving the possibility that
the hyperosteoidosis may have been a manifestation of
increased bone turnover rather than a mineralization
defect.30 Among six studies that reported bone volume per
tissue volume,30–35 only three reports (two of which limited
enrollment to osteopenic patients) found it reduced at
13–20%.31,33,35 Trabecular thickness was normal in the sole
study that examined it.34
In this study, we performed a comprehensive histomor-
phometric analysis of trabecular bone among patients with
well characterized AH and compared the results with those of
a matched control group. We found low bone formation with
reduced osteoblast surface and wall thickness. Although bone
resorption based on osteoclast surface was significantly
higher in AH, our patients and controls demonstrated
normal bone resorption when compared with reported
osteoclast surface in normal young men and premenopausal
women.36,37 Moreover, we observed markedly decreased
trabecular thickness despite normal trabecular number and
separation, which is more consistent with chronic low bone
formation than chronic high bone resorption. The low bone
formation we observed may have resulted from decreased
osteoblast recruitment, lifespan, or function. Although the
underlying cause of our histomorphometrical observations is
not clear, it is compatible with endogenous excess calcitriol
effect.19
Our histomorphometric finding of a relative excess of
bone resorption over bone formation is supported by prior
physiological–metabolic studies in idiopathic hypercalciuria.
Utilizing calcium balance studies, Liberman et al.38 reported
negative calcium balance in five of nine patients. Coe et al.39
found that during severe restriction of dietary calcium,
urinary calcium exceeded calcium intake in 16 of 27
hypercalciuric patients.39 In the control group, urinary
calcium was always less than calcium intake.
We found a nonsignificant decrement in BMD at the
lumbar spine among patients with AH. A significant
decrement in BMD at the lumbar spine was disclosed in
most,5–7,11–14,17,18,40–43 but not all33,44 prior evaluations of
hypercalciuric stone-formers. Unlike patients with secondary
hyperparathyroidism from inadequate calcium intake or
renal leak hypercalciuria,1,45 the cortical bone appears to be
spared in AH. The observed pattern of trabecular bone loss
with preservation of cortical bone in this study and our prior
publications1,5,45 is more consistent with that seen in patients
with hypogonadism or significant glucocorticoid exposure
conditions that we specifically excluded. The concomitant
Table 2 | Physiological response to alendronate in AH
Parameter Baseline Alendronate P-value
Blood Ca, mg/dl (mmol/l) 9.470.3 (2.470.1) 9.170.3 (2.370.1) 0.004
Creatinine, mg/dl (mmol/l) 0.970.2 (79.6717.7) 0.970.2 (79.6717.7) 0.35
PTH, pg/ml (ng/l) 34711 (34711) 52718 (52718) 0.0004
25-OHD, ng/ml (nmol/l) 25710 (62725) 29714 (72735) 0.23
1,25(OH)2D3, pg/ml (pmol/l) 44714 (114729) 49719 (127749) 0.13
C-telopeptides, ng/ml 0.5970.41 0.2870.19 0.007
P1NP, ng/ml 52729 50721 0.70
Urine Ca, mg/d (mmol/d) 252741 (6.371.0) 204750 (5.171.3) 0.06
Creatinine, mg/d (mmol/d) 15287425 (1350873757) 15067333 (1331372944) 0.44
N-telopeptides, nm BCE/mm Cr 35714 1979 0.007
Fasting UCa, mg/mg Cr (mmol/mmol Cr) 0.1470.07 (3967198) 0.0670.04 (1707.113) 0.001
Post-load UCa, mg/mg Cr (mmol/mmol Cr) 0.3070.07 (8487198) 0.2370.09 (6507254) 0.03
Fractional Ca absorption (%) 58.676.6 68.378.8 0.03
Estimated Ca balance (mg/day) 11725 +71746 0.007
AH, absorptive hypercalciuria; PTH; parathyroid hormone.
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low bone formation is more consistent with glucocorticoid-
induced osteoporosis.
Hypocalciuric response to alendronate has been examined
before in hypercalciuric patients and in a hypercalciuric
animal model. In an outpatient study, Weisenger et al.46
reported that urinary calcium decreased on average, 75 to
202 mg/day in patients with idiopathic hypercalciuria treated
with alendronate 10 mg/day. Urinary calcium decreased at 1
month and remained reduced for 1 year. In contrast, they
found that urinary calcium did not change with treatment in
normal volunteers. Bushinsky47 found that the urinary
calcium of hypercalciuric rats fell toward the range of wild-
type rats after treatment with subcutaneous alendronate
(50 mcg/kg/day 1 week), correcting the negative-estimated
calcium balance. Urinary calcium did not fall with alendro-
nate treatment in the control rats.
Our objective in submitting patients with AH-1 to the
alendronate challenge was to ascertain what biochemical–-
metabolic abnormalities would remain after correction of
excess bone resorption. The significant and substantial
decline in markers of bone resorption without change in
markers of bone formation indicated achievement of a
primary blockade of bone resorption. The observed physio-
logic sequelae after alendronate suggest that the bone
contributes to hypercalciuria in AH-1. The blockade of
skeletal mobilization of calcium modestly decreased serum
calcium, which raised serum PTH within the normal range.
Serum 1,25-(OH)2D3 appropriately trended higher, which
probably increased fractional calcium absorption, but the
increment in serum 1,25-(OH)2D3 did not reach significance,
possibly owing to our small sample size. Estimated calcium
balance improved because of enhanced absorption and
decreased excretion of calcium. Yet, our findings still suggest
that the intestine is the primary source of urinary calcium
because hypercalciuria persisted despite skeletal blockade.
Moreover, we have previously reported that administration of
a poorly absorbed oral calcium binder decreased 24-h urinary
calcium more efficiently in AH-1 patients.1,48 Finally, unlike
renal leak hypercalciuria, intestinal hyperabsorption in AH-1
does not correct with thiazide treatment.49
There are limitations to our study. Our study sample was
small given the difficulty of the study protocol. Another
potential weakness is that the physiologic studies occurred
during restricted calcium intake and it is possible that bone
turnover balance would have been different under higher
calcium intake. Against this possibility, bone histomorpho-
metry, which was performed before any dietary changes,
similarly demonstrated relative excess bone resorption.
Although we did not compare the physiologic response to
alendronate in AH with that in normal volunteers, previous
studies in normal volunteer humans and in control rats
reported no decrement in urinary calcium with alendronate
treatment.46,47 Four of our stone-formers had been treated
with hypocalciuric agents (three for p2 years and one for
410 years), which may prevent bone loss.50 Moreover,
Steiniche et al.51 biopsied hypercalciuric stone-formers before
and after 6 months of treatment with hydrochlorothiazide
and demonstrated decreased eroded surface, bone formation
rate, and osteoid surface. However, we found no difference
between our patients and controls in the three significant
parameters noted in the thiazide-biopsy study. Indirectly
measured calcium absorption by calciuric response to an oral
calcium load did not increase, probably owing to decreased
fasting serum and urine calcium and increased serum PTH.
Finally, estimated calcium balance may be an overestimate of
calcium balance as it does not include further external
calcium losses from endogenous fecal calcium and sweat.
In conclusion, there is a relative excess of bone resorption
over bone formation in patients with AH-1, contributing to
bone loss. Nevertheless, the persistence of hypercalciuria and
intestinal hyperabsorption of calcium after antiresorptive
therapy demonstrates the more important role of the gut on
hypercalciuria in AH-1. Given the considerable evidence that
hypercalciurics have low BMD, that hypercalciuria is a known
risk factor for osteoporosis, and that the risk of fracture is
increased in stone-formers, we suggest that evaluation of the
bone status should become standard practice in stone-
forming patients with hypercalciuria. Further work is needed
to elucidate the low bone formation phenotype in AH and to
determine which patients are at most risk for bone loss.
MATERIALS AND METHODS
Subjects
We enrolled nine well-characterized patients with AH-I (normo-
calcemia, normal serum PTH, urinary calcium 4200 mg/day on a
diet restricted in calcium and sodium, and hyperabsorption of
calcium based on a 1-g oral calcium load) with or without fasting
hypercalciuria from our kidney stone clinics.27
Among the nine stone-formers, five were Caucasian men, one
was a Caucasian-Hispanic man, and three were Caucasian
premenopausal women. Mean7s.d. for age was 4178 years (range,
28–53), for weight was 77715 kg (range, 59–98), for height was
1.770.1 m (range, 1.6–1.9), and for body mass index was
26.574.1 kg/m2 (range, 20.8–31.9). Normal volunteers were re-
cruited by advertisement (n¼ 2) or from our normal volunteer
database (n¼ 7) on the basis of the closest match to participating
patients by gender, ethnicity, age (within 10 years), and weight. They
comprised six Caucasian men and three Caucasian premenopausal
women. Mean7s.d. for age was 37712 years (range, 20–53), for
weight was 79721 kg (range, 44–104), for height was 1.770.1 m
(range, 1.5–1.9), and for body mass index was 26.77.8 kg/m2
(range, 17.5–36.0). Two patients and one normal volunteer smoked
cigarettes. One patient smoked one pack a day and the other two
subjects smoked o½ pack a day. They had no personal or family
history of kidney stones. All subjects gave informed consent for the
protocol, which was locally approved by our Institutional Review
Board.
The exclusion criteria, designed to minimize confounders
affecting the bone or calcium homeostasis, were: age o20 years or
465, hypogonadism, alcoholism, chronic liver disease, renal
insufficiency (creatinine clearanceo70 ml/min), poor general
health, poorly controlled diabetes mellitus, hyperparathyroidism
and need to continue diuretic treatment with drugs likely to impact
on the bone (agents approved to treat or prevent osteoporosis,
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significant glucocorticoid exposure, anticonvulsants). Additional
exclusion criteria, directed towards optimizing safety, were active
ulcer or esophagitis, dyspepsia requiring medication, dysphagia,
hypocalcemia, anemia, thrombocytopenia, prolonged prothrombin
time/partial thromboplastin time, bleeding disorder, allergy tetra-
cycline and known or desired pregnancy.
Protocol outline
Qualifying patients with AH were admitted to the inpatient General
Clinical Research Center (GCRC) three times. They underwent bone
biopsy during the first admission, baseline metabolic evaluation
during the second admission, and repeat metabolic evaluation after
alendronate treatment during the last admission. Only normal
volunteers participated in the initial admission for bone biopsy.
Before the initial admission, each subject was labeled with
declomycin (1st label: 750 mg daily in three divided doses for 2 days,
10-day interval; 2nd label; biopsy 5 days after 2nd label). Under local
anesthesia, each subject underwent full-thickness transiliac bone
biopsy (2.5 cm lateral and posterior to the anterior superior iliac
spine; diameter of 7.5 mm). In stone-formers and normal volun-
teers, BMD was measured by dual-energy X-ray absorptiometry
(nine stone-formers and two normal volunteers by Hologic QDR-
4500A; seven normal volunteers by Hologic QDR-2000 (Waltham,
MA, USA) at the anterior posteriar lumbar spine, femoral neck, and
the distal radius.
Before the second and third admissions, each stone-former was
stabilized on an instructed diet that was similar to the inpatient
constant metabolic diet (high fluid intake, 100 mmol Na, 10 mmol
Ca, o1.5 mmol oxalate, o10 oz animal flesh) for 3 weeks. Patients
were then maintained on a constant metabolic diet for 3 days in the
inpatient GCRC. During both admissions, fasting blood was drawn
daily, two consecutive 24-h urine collections were obtained and
intestinal calcium absorption was estimated by two methods – dual-
stable calcium isotope and oral calcium load as described
previously.27,52 For the dual-stable calcium isotope, a 2.5-mmol
Ca carrier, approximating the content of calcium during breakfast,
was given orally at 0800 in a liquid meal containing a trace amount
of a stable isotope of calcium (46Ca). A trace amount of a different
stable isotope of calcium (42Ca) was given intravenously at the same
time. For the oral calcium-load test, 25 mmol of calcium was given
with a liquid meal; 2-h and 4-h urine samples were collected
immediately before and after the oral calcium load, respectively.
Starting 2 weeks before the third admission and continuing to the
end of the study (17 days total), 10 mg oral alendronate was taken
each morning with 48 oz of water after an overnight fast and
60 min before meals or any other medication. This short duration of
treatment was chosen to allow sufficient decrement in bone
resorption with little or no effect on bone formation.53
Laboratory analyses
Serum and urine creatinine was run by an autoanalyzer (Beckman,
Synchron CX9ALX, Brea, CA). Serum and urine Ca was analyzed by
atomic absorption spectrophotometry (Varian, Sunnyvale, CA,
USA). ‘Intact’ PTH was measured by ELISA (ALPCO Diagnostics,
Windham, NH). This assay has a calculated sensitivity of 0.9 pg/ml
and intra- and interassay coefficients of variation (CVs) of 3.2 and
7.7%, respectively. Serum 25-hydroxyvitamin D (25-OHD) was
measured by ELISA (OCTEIA, ALPCO Diagnostics, Windham,
NH). The sensitivity is 5 nmol/l and the intra- and interassay CVs
are 6.7 and 8.7%, respectively. Serum 1,25(OH)2D3 was determined
by competitive enzyme immunoassay (ALPCO Diagnostics, Wind-
ham, NJ). Samples were first extracted and purified on small
chromabond and silica columns and then assayed. This assay has a
detection limit of 4.8 pg/ml and intra- and interassay CVs of 6.6 and
9.0%, respectively. Serum cross-linked carboxyterminal telopeptide
of type I collagen (CTX; serum Crosslapss, Nordic Bioscience
Diagnostics, Herlev, Denmark) was quantitated by ELISA. The intra-
and interassay CVs are 5.1 and 8.1%, respectively. The detection
limit is 0.010 ng/ml. Serum procollagen I N-terminal propeptide was
quantitated by radioimmunoassay (PINP; UniQTM PINP, Orion
Diagnostica, Espoo, Finland). Detection limit and CVs are 2 ng/ml,
and 8 and 8.2%, respectively. Urinary cross-linked N-terminal
telopeptide of type I collagen (NTX; Ostex International, Osteo-
marks, Seattle, WA, USA) was assessed by ELISA. The intra- and
interassay CVs are both 20%. All samples for a given individual were
analyzed in the same assay to minimize the effects of interassay
variability.
Fasting urinary calcium was expressed as mg/mg urinary
creatinine in 2-h fasting sample. Post-load urinary calcium was also
expressed as mg/mg creatinine from 4-h post-load samples.
Fractional calcium absorption was derived by measuring the ratio
of recovered oral calcium isotope to the recovered intravenous
isotope in the 24-h urine collection following administration of the
isotopes using mass spectrometry. Isotope analyses were performed
by Dr Steven Abrams at Baylor College of Medicine (Houston, TX).
This method has been shown to be highly correlated (r¼ 0.90) with
a more rigorous technique based on deconvolution of stable calcium
turnover.54 Estimated calcium balance was approximated by
subtracting mean urinary calcium from estimated dietary calcium
absorption ((400 mg of dietary calcium fractional calcium absorp-
tion/100)24-h urinary Calcium).52
Static and dynamic histomorphometry
Bone specimens were prestained in Villanueva Osteochrome
(Polysciences Inc., Warrington, PA, USA). After dehydration in
increasing concentrations of alcohol, the specimens were embedded
in methylmethacrylate and kept at 373C until fully polymerized.
They were then sectioned on a Reichert–Jung Polycut model E
microtome (Heidelberg, Germany) at a thickness of 10 mm. A total
of six sequential sections were cut from each specimen. Sections 1, 3,
and 5 were mounted directly to slides and were examined under UV
light for tetracycline uptake assessment. Sections 2, 4, and 6 were
mounted to slides, deplasticized in xylene, stained with toluidine
blue, and were examined for static measurements. Histomorpho-
metric measurements were made with an Aus Jena microscope (Carl
Zeiss, Jena, Germany), a video camera, and an image-capture
program that allowed quantitation of the various length, thickness,
and area parameters (Bioquant Bone Morphometry Program, R&M
Biometrics, Nashville, TN). Nomenclature recommended by the
Committee on Bone Histomorphometry of the American Society for
Bone and Mineral Research was used.55 All specimens were read by a
single investigator uninvolved with patient care (J.E.Z.).
Statistical analysis
Differences between baseline and treatment phases were assessed
with paired t-tests except for skewed data (observed only with
P1NP), which were evaluated using Wilcoxon signed rank test. The
Wilcoxon rank sum test was used to compare histomorphometric
variables and BMD between stone former and control groups.
Statistical analysis was performed using SAS version 9.1 (SAS
Institute, Cary, NC). Results are expressed as mean7s.d. unless
otherwise noted. Analysis of fractional calcium absorption was
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limited to seven of the stone-formers because technical difficulties
invalidated the test in one phase in two subjects.
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